[EN] COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DES CYCLES FUSIONNÉS QUI INHIBENT L'ACTIVITÉ BÊTA SECRÉTASE ET LEURS MÉTHODES D'UTILISATION
申请人:COMENTIS INC
公开号:WO2011130383A1
公开(公告)日:2011-10-20
The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.
这项发明提供了新型β-分泌酶抑制剂及其使用方法,包括治疗阿尔茨海默病的方法。
Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor
relationships (SARs) study of novel positiveallostericmodulators (PAMs) of the M3 mAChR through a high throughput screening (HTS) campaign. Compound 9 exhibited potent in vitro PAM activity towards the M3 mAChR and significant enhancement of muscle contraction in a concentration-dependent manner when applied to isolated smooth muscle strips of rat bladder. Compound 9 also showed excellent subtype selectivity
A Simple Stereoselective Synthesis of Enantiopure 2-Substituted Pyrrolidines and Piperidines from Chiral (R)-Phenylglycinol-Derived Bicyclic 1,3-Oxazolidines
作者:José M. Andrés、Ignacio Herráiz-Sierra、Rafael Pedrosa、Alfonso Pérez-Encabo
Chiral, nonracemic 2-substituted pyrrolidines and piperidines were prepared in high ee and moderate to good chemical yields in three steps from (R)-phenylglycinol and γ- or δ-chloroketones. The key step of the synthesis was the stereoselective reductive ring-opening of chiral bicyclic 1,3-oxazolidines prepared by condensation of (R)-phenylglycinol and the corresponding ketones.
手性、非外消旋的 2-取代吡咯烷和哌啶通过三个步骤从 (R)-苯基甘氨醇和 γ-或 δ-氯酮以高 ee 和中等至良好的化学产率制备。合成的关键步骤是通过 (R)-苯基甘氨醇和相应的酮缩合制备的手性双环 1,3-恶唑烷的立体选择性还原开环。
[EN] MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS<br/>[FR] PYRRAZOLES FUSIONNÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE MCL-1
申请人:ASCENTAGE PHARMA SUZHOU CO LTD
公开号:WO2020151738A1
公开(公告)日:2020-07-30
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.